Topic: Lymphoma · Referral · Coverage schemes

Diagnosed With Lymphoma and Told to Find Treatment at Another Hospital: 7 Documents to Request, Using Thai Coverage Schemes, Outlook by Subtype and Coping on Day One

AI Overview / Quick Answer (BLUF)

Before discharge, request your treatment summary, pathology report with slides and tissue blocks, scan images, blood results and a referral letter, then book the receiving cancer center. Many lymphomas, including Hodgkin and DLBCL, are curable; others can be controlled for years, depending on subtype and stage.

Who this is for:
patients and families who have just learned the diagnosis is lymphoma (NCI) and have been told to continue treatment at another hospital ·
Warning signs ·
Document checklist ·
Coverage schemes ·
Subtypes and outlook ·
Treatments compared ·
FAQ

A patient’s voice: the results say lymphoma, and I have to leave hospital tomorrow to find treatment myself

Short answer: feeling like it is a nightmare is completely normal, and you do not need to understand everything on day one. What you can do right now is collect every document before discharge and ask the hospital to help arrange the next appointment.

A patient shared that he had just learned he has lymphoma and must leave hospital the next day to find somewhere to continue treatment. This article summarizes what to request, which coverage you can use, the evidence on outlook and the symptoms that cannot wait. It does not assess his personal history, so it is not a diagnosis.

1. What lymphoma is, and why many types are curable

Short answer: lymphoma arises from white blood cells called lymphocytes and responds to chemotherapy, antibody drugs and radiotherapy better than many solid cancers. But there are dozens of subtypes, so the outlook varies widely.

89–94%6-year overall survival in stage III–IV Hodgkin lymphoma in a 1,334-patient trial
76% vs 63%Complete response when rituximab was added to chemotherapy in DLBCL, age 60–80
43.5% vs 27.6%10-year overall survival in the same group, including deaths from other age-related causes
19.7%Diagnoses that changed after expert pathology review

Cured versus controlled

In stage III–IV Hodgkin lymphoma, the ECHELON-1 trial (Ansell 2022) found 6-year overall survival of 93.9% with a brentuximab vedotin-containing regimen and 89.4% with the standard regimen.
In diffuse large B-cell lymphoma (DLBCL), the most common type, adding rituximab to CHOP chemotherapy (Coiffier 2002) raised the complete-response rate from 63% to 76%, and at 10 years (Coiffier 2010) overall survival was 43.5% versus 27.6% in patients aged 60–80. Relapses after 5 years made up only 7% of all relapses.
Slow-growing types such as follicular lymphoma can often be controlled for many years but may return, so the goal is long-term control rather than being cured with one course of treatment.

How staging is done

The Lugano classification (Cheson 2014) uses PET-CT as standard staging for tracer-avid lymphomas and no longer requires routine bone-marrow biopsy in Hodgkin lymphoma and most DLBCL. Treatment is planned for limited disease (non-bulky stage I–II) or advanced disease (stage III–IV). Stage III–IV lymphoma therefore does not carry the same meaning as advanced stage in many solid cancers.

A general overview; actual prognosis depends on stage, age and individual risk factors (shown as cards on mobile)

Common subtypes, disease behavior, treatment goal and what to ask your doctor
SubtypeBehaviorTreatment goalWhat to ask
Hodgkin lymphomaCommon in young adults; often starts in neck or chest nodesAim to be cured, even at stage III–IVStage, risk factors, and egg or sperm storage before treatment
DLBCL (aggressive B-cell)Most common type; masses grow over weeksMany patients are curedRisk score (IPI) and how quickly treatment should start
Follicular and marginal zone (slow-growing)Grows over years; some people have no symptomsLong-term control; some can be watched firstDo I need treatment now, or close monitoring?
Mantle cell lymphomaLess common; both slow and aggressive formsControl for as long as possibleWhether stem-cell transplant or targeted drugs suit me
T-cell lymphomaLess common than B-cell; drug response variesDepends on subtype; some are harder to treatExperienced centers and clinical trials I can join

2. A 7-document checklist to request from the first hospital before you move

Short answer: complete documents mean the new hospital does not need to repeat the biopsy or scans, so treatment starts sooner. The item most often forgotten is the biopsy slides and blocks.

Always keep one copy for yourself (shown as cards on mobile)

Document, why it matters, what it must contain and how to request it
DocumentWhy it mattersMust containHow to request
1. Treatment summaryGives the new doctor the full picture in minutesSymptoms, test results, procedures, medicines and other conditionsAsk on the ward before discharge
2. Pathology reportConfirms cancer and the subtypeSubtype and special stains such as CD20, CD30, Ki-67Copy from your doctor or medical records
3. Biopsy slides and blocksLets the receiving pathologist review or re-stain without a new biopsyStained slides and paraffin blocksLoan request at the pathology unit; may take 1–3 days
4. ScansAllows staging without an immediate repeat scanCT or PET-CT image files plus reportsAsk radiology for files on a disc or drive
5. Latest blood resultsUsed to judge readiness for treatmentBlood counts, LDH, liver and kidney function, hepatitis results if doneCopy of lab results
6. Medicine list and allergiesPrevents duplication and interactionsMedicines given in hospital, including any steroidsAsk the ward pharmacist or nurse
7. Referral letter or coverage certificateNeeded to bill your coverage schemeReceiving hospital, diagnosis and period coveredReferral center or coverage office

Why the slides and blocks matter so much

A French expert lymphoma pathology network (Laurent 2017) reviewed 42,145 samples and found the diagnosis changed after review in 19.7% of patients, affecting care in 17.4%. Most changes were reclassifications of subtype (41.3% of changes), which can change the drug regimen. When samples arrived with a formal diagnosis, only 3.7% changed; when sent for a second opinion, 37.8% changed.
Bringing the slides and blocks lets the new team review immediately without another surgical biopsy.

If you must leave hospital tomorrow, what to do tonight

3. Using Universal Coverage (Cancer Anywhere), Social Security and the civil-servant scheme

Short answer: each scheme has different steps. Always call the receiving hospital’s coverage office before you travel so you do not make a wasted trip.

Rules may change each fiscal year; confirm directly with the agency (shown as cards on mobile)

Coverage scheme, how to use it when moving hospitals, where to ask and what to know
SchemeHow to use it when movingWhere to askWhat to know
Universal Coverage (Cancer Anywhere)Once diagnosed, attend any equipped hospital in the network, in many cases without a referral letterNHSO hotline 1330 and the receiving cancer centerYou still need an appointment, and confirmed pathology helps
Social SecurityTreated at your registered hospital; a referral letter is needed if care exceeds its capacitySocial Security Office hotline 1506A separate system from Universal Coverage; do not mix the steps
Civil servants and familiesDirect billing at public hospitals is generally availableThe receiving hospital’s coverage officeSome medicines need prior approval
Private health insuranceCheck limits and network hospitals firstYour insurer or agentSome high-cost drugs may exceed limits; ask before starting

How well Cancer Anywhere works in practice

The policy, in place since 2021, means Universal Coverage patients with a confirmed diagnosis no longer need a new referral letter each time. It does not mean you can walk into any hospital and start treatment the same day: the cancer center still reviews pathology, completes staging and schedules a queue. Booking ahead with all 7 documents helps most.

Check how urgent your symptoms are while you wait to start treatment

Waiting for the new hospital and unsure whether a symptom can wait for the appointment or needs the emergency room?

Get a severity analysis and personalized guidance from our Advisory team. The assessment sorts the urgency of symptoms during cancer care; it does not diagnose any disease and does not replace seeing a doctor. If you have warning signs, call emergency services immediately.

Take the Cancer-Care Warning-Sign Score (free)

4. How long you can wait, and the checks needed before treatment starts

Short answer: urgency depends on how aggressive the disease is. Not everyone must start on the same day, but do not go a week without an appointment, and use the waiting time to prepare.

Research on time from diagnosis to treatment

A study of DLBCL patients in the United States (986) and Europe (1,444) (Maurer 2018) found median times from diagnosis to treatment of 15 and 23 days. People who started fastest tended to have more aggressive disease, such as high LDH, poor performance status, fevers or weight loss, so their worse results reflected the disease rather than the speed of starting.
The practical takeaway: waiting a few days to complete tests does not necessarily worsen outcomes, but people with severe symptoms need care quickly.

Hepatitis B testing before treatment

ASCO guidance (Hwang 2020) recommends that everyone starting systemic cancer therapy be tested for hepatitis B with three tests (HBsAg, anti-HBc and anti-HBs) without delaying treatment. People with past infection who will receive anti-CD20 antibodies or stem-cell transplantation should receive antiviral prophylaxis during treatment and for at least 12 months afterwards, because hidden virus can reactivate and cause severe hepatitis.

If you may want children, discuss it before treatment

ASCO guidance (Oktay 2018) advises discussing fertility as early as possible before treatment. Sperm, egg and embryo freezing are standard; ovarian-suppression drugs should not replace proven methods. Lymphoma can affect young adults, so raise this at the first appointment.

5. Modern treatment options: chemotherapy, antibodies, immunotherapy, CAR-T and transplant

Short answer: most first treatments combine chemotherapy with an antibody drug. CAR-T, stem-cell transplant and some newer drugs are mostly used when the disease does not respond or comes back.

In DLBCL, the POLARIX trial (Tilly 2022) of 879 patients found that replacing vincristine with polatuzumab vedotin gave 2-year progression-free survival of 76.7% versus 70.2%, while 2-year overall survival was similar (88.7% and 88.6%).
When disease did not respond or relapsed within 12 months, the ZUMA-7 trial (Westin 2023) of 359 patients found CAR-T raised 4-year overall survival to 54.6% versus 46.0% with standard care.

Options compared using generic names and drug classes only (shown as cards on mobile)

Treatment, how it works, who it suits and what to know
TreatmentHow it worksWho it suitsWhat to know
Combination chemotherapy (e.g. CHOP, ABVD)Several drugs kill fast-dividing cellsFirst treatment for aggressive types and HodgkinFever after treatment means go to hospital at once
Anti-CD20 antibody (rituximab)Binds CD20 on B cells so the immune system destroys themCD20-positive B-cell typesHepatitis B testing is needed first
Antibody-drug conjugates (polatuzumab vedotin, brentuximab vedotin)Deliver chemotherapy into cancer cells carrying CD79b or CD30Some DLBCL and advanced HodgkinMay cause numbness in hands and feet
RadiotherapyTargets the area with the massLimited stage, bulky masses or symptom reliefOften combined with drugs; not everyone needs it
PD-1 inhibitor immunotherapy and bispecific antibodiesRelease immune brakes or bring T cells to cancer cellsMostly relapsed diseaseCoverage varies by scheme; ask first
CAR-T (e.g. axicabtagene ciloleucel)The patient’s own T cells are engineered to target cancer cellsRefractory or early-relapsed diseaseAvailable at specialist centers; high cost
Autologous stem-cell transplantHigh-dose chemotherapy followed by return of your stem cellsRelapsed disease that still responds to drugsNot the first treatment for most people
Active monitoringSymptoms and tests are tracked without drugs yetSlow-growing types without symptomsNot neglect; appointments must be kept
Herbs or supplements instead of treatmentNo evidence they treat lymphomaNot recommended as a substituteSome interact with chemotherapy or harm the liver; tell your doctor

6. Holding on emotionally on the day of bad news: for patients and families

Short answer: fear, shock and sleeplessness early on are common, and you can ask for help from day one; you do not need to wait until you cannot cope.

How common emotional distress is

A pooled analysis of 70 studies and 10,071 patients in oncology and hematology settings (Mitchell 2011) found depression in 16.3%, adjustment disorder in 19.4% and anxiety in 10.3%; any mood disorder reached 38.2%. Feeling like you are in a nightmare does not mean you are weak.

What actually helps in the first week

  • Choose one family member as the main coordinator and keep all questions and answers in one notebook
  • Ask your doctor three things: which subtype, which stage, and what the goal of treatment is
  • Ask to see the hospital social worker about travel costs, accommodation and coverage
  • Use trustworthy sources and avoid posts selling herbs or promising fast results
  • If you cannot sleep for several nights, cry all day, or think about harming yourself, tell your doctor or call Thailand’s mental health hotline 1323

Frequently asked questions (FAQ)

Questions patients and families often ask on the first day of diagnosis and transfer

I have just been diagnosed with lymphoma and must leave hospital to find treatment elsewhere. Which documents should I request?

Request seven things before discharge: a treatment summary, the pathology report with special stains, the biopsy slides and paraffin blocks (on loan), scan images with their reports, your latest blood results, a list of medicines given and any drug allergies, and a referral letter or coverage certificate. Also ask your doctor or the referral center to arrange an appointment with the receiving hospital before you leave.

Can lymphoma really be cured?

Many types are curable, but it depends on the subtype and stage. In stage III–IV Hodgkin lymphoma, a large trial found 6-year overall survival of about 89–94%. In diffuse large B-cell lymphoma, the most common type, adding rituximab to chemotherapy raised 10-year survival in patients aged 60–80 from 27.6% to 43.5%. Slow-growing types such as follicular lymphoma can often be controlled for many years but may come back, so ask your doctor which subtype you have and what the goal of treatment is.

How does Thailand’s Universal Coverage Cancer Anywhere policy work, and do I need a referral letter?

Since 2021, the National Health Security Office has allowed Universal Coverage patients with a confirmed cancer diagnosis to be treated at any equipped hospital in its network, in many cases without a referral letter. Receiving hospitals usually still need confirmed pathology and run an appointment queue, so call the destination cancer center before you go, bring your ID card and all documents, and call the NHSO hotline 1330 if unsure.

Can I move hospitals under the Social Security or civil-servant scheme?

Yes, but the steps differ. Under Social Security you are normally treated at your registered hospital, which must issue a referral letter if your care exceeds its capacity; the hotline is 1506. The civil-servant scheme generally allows direct billing at public hospitals, but some medicines need prior approval. Always check with the receiving hospital’s coverage office before starting treatment.

Why do I need to borrow the biopsy slides and blocks? Isn’t the pathology report enough?

Because lymphoma treatment depends on the exact subtype, which requires several special stains, and the receiving hospital often wants to review the tissue or stain it again. A French expert pathology network that reviewed 42,145 samples found the diagnosis changed after expert review in 19.7% of patients, with an impact on care in 17.4%. Bringing the slides and blocks avoids a repeat biopsy and helps treatment start sooner.

Will waiting several days for the new hospital let lymphoma spread?

It depends on how aggressive the disease is. A study of 2,430 patients with diffuse large B-cell lymphoma in two cohorts found median times from diagnosis to treatment of 15 and 23 days, and the people who had to start treatment fastest were those with more aggressive disease to begin with. A wait of a few days to complete tests does not necessarily worsen outcomes, but do not go a week without an appointment, and go to the emergency room at once for rapid growth, breathing difficulty, facial swelling or leg weakness.

What roles do targeted therapy, immunotherapy and CAR-T play in lymphoma treatment?

Anti-CD20 antibodies such as rituximab combined with chemotherapy are standard for B-cell lymphomas. Antibody-drug conjugates such as polatuzumab vedotin and brentuximab vedotin improve results in some types. CAR-T is used when the disease does not respond or comes back; one trial found 4-year overall survival of 54.6% versus 46.0% with standard care. The choice depends on subtype, stage and coverage.

What extra tests or preparation are needed before starting lymphoma chemotherapy?

Ask about three things: hepatitis B testing, because anti-CD20 drugs can reactivate a hidden infection, and ASCO guidance recommends testing before treatment and antiviral prophylaxis for people with past infection; egg or sperm storage if you may want children, discussed before treatment starts; and a heart check before drugs that can affect the heart. These checks should not delay treatment.

Scientific mechanism

Summary by :
lymphoma develops when B or T lymphocytes acquire genetic changes, such as translocations of genes that control cell division or cell death, so the cells keep dividing in lymph nodes, the spleen or other organs.
Aggressive types divide often, which makes them sensitive to chemotherapy that damages DNA during division. Most B cells display CD20 on their surface, so anti-CD20 antibodies bind the cancer cells and trigger complement and immune cells to destroy them. Antibody-drug conjugates deliver chemotherapy directly into cells carrying CD79b or CD30.
CAR-T uses the patient’s own T cells fitted with a synthetic receptor against CD19, allowing them to kill B cells even after chemotherapy resistance. Knowing the subtype and surface proteins from the biopsy stains therefore determines which treatment will work, and is why the slides and blocks must travel with you to the new hospital.

Academic citations (E-E-A-T)

  1. Coiffier B, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002.
  2. Coiffier B, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients. Blood 2010.
  3. Tilly H, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 2022.
  4. Ansell SM, et al. Overall survival with brentuximab vedotin in stage III or IV Hodgkin’s lymphoma. N Engl J Med 2022.
  5. Westin JR, et al. Survival with axicabtagene ciloleucel in large B-cell lymphoma. N Engl J Med 2023.
  6. Laurent C, et al. Impact of expert pathologic review of lymphoma diagnosis: study of patients from the French Lymphopath network. J Clin Oncol 2017.
  7. Maurer MJ, et al. Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials. J Clin Oncol 2018.
  8. Cheson BD, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014.
  9. Hwang JP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. J Clin Oncol 2020.
  10. Oktay K, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 2018.
  11. Mitchell AJ, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol 2011.

Compiled and reviewed by · Generic names and drug classes only; no trade names of drugs or products.

Medical Disclaimer

This article is educational information based on research and international clinical guidelines. It is not a diagnosis, not a treatment prescription and not a substitute for seeing a doctor. Outlook and treatment regimens depend on subtype, stage and individual health. Coverage rules may change each year; confirm with the agency and hospital directly. Do not stop or change treatment on your own, and if you have warning signs, call emergency services or go to the emergency room immediately.